The neurobiology of relapse in schizophrenia

Schizophrenia Research

Volumn 152, Issue 2-3, 2014, Pages 381-390

  Remington, Gary ^a,b,c   Foussias, George ^a,b,c   Agid, Ofer ^a,b   Fervaha, Gagan ^b,c   Takeuchi, Hiroyoshi ^a,b   Hahn, Margaret ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Neurobiology; Outcome; Psychosis; Relapse; Response; Schizophrenia

Indexed keywords

DOPAMINE; NEUROLEPTIC AGENT;

ARTICLE; BRAIN ELECTROPHYSIOLOGY; CHRONIC DRUG ADMINISTRATION; DISEASE EXACERBATION; DOPAMINERGIC TRANSMISSION; DRUG RESPONSE; DRUG TOLERANCE; HORMONAL REGULATION; HUMAN; ILLNESS BEHAVIOR; IMMUNE DYSREGULATION; LIFE STRESS; NEUROBIOLOGY; NEUROPATHOLOGY; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RELAPSE; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SUBSTANCE ABUSE; TREATMENT REFUSAL;

NEUROBIOLOGY; OUTCOME; PSYCHOSIS; RELAPSE; RESPONSE; SCHIZOPHRENIA;

FEMALE; HUMANS; MALE; NEUROBIOLOGY; RECURRENCE; SCHIZOPHRENIA;

EID: 84892852653     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.10.009     Document Type: Article

References (176)

1. Abdel-Baki A., Ouellet-Plamondon C., Malla A. Pharmacotherapy challenges in patients with first-episode psychosis. J. Affect. Disord. 2012, 138(14):9.
2. Abi-Dargham A., van de Giessen E., Slifstein M., Kegeles L.S., Laruelle M. Baseline and amphetamine-stimulated dopamine activity are related in drug-naive schizophrenic subjects. Biol. Psychiatry 2009, 65(12):1091-1093.
3. Aghajanian G.K. LSD and CNS transmission. Annu. Rev. Pharmacol. 1972, 12:157-168.
4. Agid O., Arenovich T., Sajeev G., Zipursky R.B., Kapur S., Foussias G., Remington G. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J. Clin. Psychiatry 2011, 72:1439-1444.
5. Agius M., Nandra K.S. Do atypical antipsychotics promote neurogenesis as a class effect?. Psychiatr. Danub. 2012, 24(Suppl. 1):S191-S193.
6. American Psychiatric Association Practice guideline for the treatment of patients with schizophrenia. Am. J. Psychiatry 2004, 1-140. (Suppl.).
7. American Psychiatric Association (APA) The dexamethasone suppression test: an overview of its current status in psychiatry. The APA Task Force on Laboratory Tests in Psychiatry. Am. J. Psychiatry 1987, 144(10):1253-1262.
8. Andreasen N.C. Negative symptoms in schizophrenia. Definition and reliability. Arch. Gen. Psychiatry 1982, 39(7):784-788.
9. Andreasen N.C., Nopoulos P., Magnotta V., Pierson R., Ziebell S., Ho B.C. Progressive brain change in schizophrenia: a prospective longitudinal study of first-episode schizophrenia. Biol. Psychiatry 2011, 70(7):672-679.
10. Andreasen N.C., Liu D., Ziebell S., Vora A., Ho B.C. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am. J. Psychiatry 2013, 170:609-615.
11. Andrews H.B., House A.O., Cooper J.E., Barber C. The prediction of abnormal evoked potentials in schizophrenic patients by means of symptom pattern. Br. J. Psychiatry 1986, 149:46-50.
12. Angrist B., Sathananthan G., Gershon S. Behavioral effects of L-dopa in schizophrenic patients. Psychopharmacologia 1973, 31(1):1-12.
13. Angrist B., Rotrosen J., Gershon S. Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia. Psychopharmacology (Berl.) 1980, 72(1):17-19.
14. Angrist B., Rotrosen J., Gershon S. Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects. Psychopharmacology (Berl.) 1980, 67(1):31-38.
15. Angrist B., Peselow E., Rubinstein M., Wolkin A., Rotrosen J. Amphetamine response and relapse risk after depot neuroleptic discontinuation. Psychopharmacology (Berl.) 1985, 85(3):277-283.
16. Arranz M.J., Rivera M., Munro J.C. Pharmacogenetics of response to antipsychotics in patients with schizophrenia. CNS Drugs 2011, 25(11):933-969.
17. Ascher-Svanum H., Zhu B., Faries D.E., Salkever D., Slade E.P., Peng X., Conley R.R. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry 2010, 10:2.
18. Belcher A.M., O'Dell S.J., Marshall J.F. Long-term changes in dopamine-stimulated gene expression after single-day methamphetamine exposure. Synapse 2009, 63(5):403-412.
19. Berridge M.J., Prince W.T. The nature of the binding between LSD and a 5-HT receptor: a possible explanation for hallucinogenic activity. Br. J. Pharmacol. 1974, 51(2):269-278.
20. Betensky J.D., Robinson D.G., Gunduz-Bruce H., Sevy S., Lencz T., Kane J.M., Malhotra A.K., Miller R., McCormack J., Bilder R.M., Szeszko P.R. Patterns of stress in schizophrenia. Psychiatry Res. 2008, 160(1):38-46.
21. Bob P., Susta M., Glaslova K., Pavlat J., Raboch J. Lateralized electrodermal dysfunction and complexity in patients with schizophrenia and depression. Neuro Endocrinol. Lett. 2007, 28(1):11-15.
22. 11C]raclopride/positron emission tomography study in healthy men. Arch. Gen. Psychiatry 2006, 63(12):1386-1395.
23. Boonstra G., van Haren N.E., Schnack H.G., Cahn W., Burger H., Boersma M., de Kroon B., Grobbee D.E., Hulshoff Pol H.E., Kahn R.S. Brain volume changes after withdrawal of atypical antipsychotics in patients with first-episode schizophrenia. J. Clin. Psychopharmacol. 2011, 31(2):146-153.
24. Boutros N.N., Mucci A., Diwadkar V., Tandon R. Negative symptoms in schizophrenia. Clin. Schizophr. Relat. Psychoses 2013, 1-33.
25. Bowers M.B. 5-Hydroxyindoleacetic acid (5HIAA) and homovanillic acid (HVA) following probenecid in acute psychotic patients treated with phenothiazines. Psychopharmacologia 1973, 28(4):309-318.
26. Bowers M.B. Central dopamine turnover in schizophrenic syndromes. Arch. Gen. Psychiatry 1974, 31(1):50-54.
27. Bowers M.B., Heninger G.R., Gerbode F. Cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in psychiatric patients. Int. J. Neuropharmacol. 1969, 8(3):255-262.
28. Brunelin J., d'Amato T., van Os J., Cochet A., Suaud-Chagny M.F., Saoud M. Effects of acute metabolic stress on the dopaminergic and pituitary-adrenal axis activity in patients with schizophrenia, their unaffected siblings and controls. Schizophr. Res. 2008, 100(1-3):206-211.
29. Brunelin J., d'Amato T., Van Os J., Costes N., Suaud Chagny M.F., Saoud M. Increased left striatal dopamine transmission in unaffected siblings of schizophrenia patients in response to acute metabolic stress. Psychiatry Res. 2010, 181(2):130-135.
30. Buchsbaum M.S. Evidence, evidence-based medicine, and evidence utility in psychiatry and electrophysiology. Clin. EEG Neurosci. 2009, 40(2):143-145.
31. Buckley P.F., Mahadik S., Pillai A., Terry A. Neurotrophins and schizophrenia. Schizophr. Res. 2007, 94(1-3):1-11.
32. Butler P.D., Chen Y., Ford J.M., Geyer M.A., Silverstein S.M., Green M.F. Perceptual measurement in schizophrenia: promising electrophysiology and neuroimaging paradigms from CNTRICS. Schizophr. Bull. 2012, 38(1):81-91.
33. Callaghan R.C., Cunningham J.K., Allebeck P., Arenovich T., Sajeev G., Remington G., Boileau I., Kish S.J. Methamphetamine use and schizophrenia: a population-based cohort study in California. Am. J. Psychiatry 2012, 169(4):389-396.
34. Canadian Psychiatric Association Clinical practice guidelines: treatment of schizophrenia. Can. J. Psychiatry 2005, 50(Suppl. 1):1S-56S.
35. Carpenter W.T., Heinrichs D.W., Wagman A.M. Deficit and nondeficit forms of schizophrenia: the concept. Am. J. Psychiatry 1988, 145(5):578-583.
36. Caseiro O., Perez-Iglesias R., Mata I., Martinez-Garcia O., Pelayo-Teran J.M., Tabares-Seisdedos R., Ortiz-Garcia de la Foz V., Vazquez-Barquero J.L., Crespo-Facorro B. Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study. J. Psychiatr. Res. 2012, 46(8):1099-1105.
37. Ceskova E., Kasparek T., Zourkova A., Prikryl R. Dexamethasone suppression test in first-episode schizophrenia. Neuro Endocrinol. Lett. 2006, 27(4):433-437.
38. Chabungbam G., Avasthi A., Sharan P. Sociodemographic and clinical factors associated with relapse in schizophrenia. Psychiatry Clin. Neurosci. 2007, 61(6):587-593.
39. Chouinard G., Chouinard V.A. Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychother. Psychosom. 2008, 77(2):69-77.
40. Chouinard G., Jones B.D. Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am. J. Psychiatry 1980, 137(1):16-21.
41. Ciudad A., San L., Bernardo M., Olivares J.M., Polavieja P., Valladares A., Gilaberte I. Relapse and therapeutic interventions in a 1-year observational cohort study of nonadherent outpatients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2012, 36(2):245-250.
42. Corcoran C., Gallitano A., Leitman D., Malaspina D. The neurobiology of the stress cascade and its potential relevance for schizophrenia. J. Psychiatr. Pract. 2001, 7(1):3-14.
43. Corcoran C., Walker E., Huot R., Mittal V., Tessner K., Kestler L., Malaspina D. The stress cascade and schizophrenia: etiology and onset. Schizophr. Bull. 2003, 29(4):671-692.
44. Cropley V., Wood S.J., Pantelis C. Brain structural, neurochemical and neuroinflammatory markers of psychosis onset and relapse: Is there evidence for a psychosis relapse signature?. Int. Clin. Psychopharmacol. 2013, (in press, May 15, Epub ahead of print).
45. Crow T.J. Positive and negative schizophrenic symptoms and the role of dopamine. Br. J. Psychiatry 1980, 137:383-386.
46. Dawson M.E., Nuechterlein K.H., Schell A.M. Electrodermal anomalies in recent-onset schizophrenia: relationships to symptoms and prognosis. Schizophr. Bull. 1992, 18(2):295-311.
47. Dawson M.E., Nuechterlein K.H., Schell A.M., Gitlin M., Ventura J. Autonomic abnormalities in schizophrenia. State or trait indicators?. Arch. Gen. Psychiatry 1994, 51(10):813-824.
48. Dawson M.E., Schell A.M., Rissling A., Ventura J., Subotnik K.L., Nuechterlein K.H. Psychophysiological prodromal signs of schizophrenic relapse: a pilot study. Schizophr. Res. 2010, 123(1):64-67.
49. Demjaha A., MacCabe J.H., Murray R.M. How genes and environmental factors determine the different neurodevelopmental trajectories of schizophrenia and bipolar disorder. Schizophr. Bull. 2012, 38(2):209-214.
50. Dinzeo T.J., Cohen A.S., Nienow T.M., Docherty N.M. Arousability in schizophrenia: relationship to emotional and physiological reactivity and symptom severity. Acta Psychiatr. Scand. 2008, 117(6):432-439.
51. Dissanayake D.W., Zachariou M., Marsden C.A., Mason R. Effects of phencyclidine on auditory gating in the rat hippocampus and the medial prefrontal cortex. Brain Res. 2009, 1298:153-160.
52. Docherty N.M., St-Hilaire A., Aakre J.M., Seghers J.P. Life events and high-trait reactivity together predict psychotic symptom increases in schizophrenia. Schizophr. Bull. 2009, 35(3):638-645.
53. Docherty N.M., St-Hilaire A., Aakre J.M., Seghers J.P., McCleery A., Divilbiss M. Anxiety interacts with expressed emotion criticism in the prediction of psychotic symptom exacerbation. Schizophr. Bull. 2011, 37(3):611-618.
54. Dossenbach M., Arango-Davila C., Silva Ibarra H., Landa E., Aguilar J., Caro O., Leadbetter J., Assuncao S. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. J. Clin. Psychiatry 2005, 66(8):1021-1030.
55. D'Souza D.C., Sewell R.A., Ranganathan M. Cannabis and psychosis/schizophrenia: human studies. Eur. Arch. Psychiatry Clin. Neurosci. 2009, 259(7):413-431.
56. Emsley R., Oosthuizen P., Koen L., Niehaus D., Martinez L. Comparison of treatment response in second-episode versus first-episode schizophrenia. J. Clin. Psychopharmacol. 2013, 33(1):80-83.
57. Evins A.E., Green A.I., Kane J.M., Murray R.M.S. Does using marijuana increase the risk for developing schizophrenia?. J. Clin. Psychiatry 2013, 74(4):e08.
58. Fallon P., Dursun S.M. A naturalistic controlled study of relapsing schizophrenic patients with tardive dyskinesia and supersensitivity psychosis. J. Psychopharmacol. 2011, 25(6):755-762.
59. Falloon I.R. Relapse: a reappraisal of assessment of outcome in schizophrenia. Schizophr. Bull. 1984, 10(2):293-299.
60. Freedman D.X. Effects of LSD-25 on brain serotonin. J. Pharmacol. Exp. Ther. 1961, 134:160-166.
61. Galderisi S., Mucci A., Volpe U., Boutros N. Evidence-based medicine and electrophysiology in schizophrenia. Clin. EEG Neurosci. 2009, 40(2):62-77.
62. Gerlach J., Luhdorf K. The effect of L-dopa on young patients with simple schizophrenia, treated with neuroleptic drugs: a double-blind cross-over trial with Madopar and placebo. Psychopharmacologia 1975, 44(1):105-110.
63. Gilbertson M.W., Yao J.K., van Kammen D.P. Memory and plasma HVA changes in schizophrenia: are they episode markers?. Biol. Psychiatry 1994, 35(3):203-206.
64. Gleeson J.F., Alvarez-Jimenez M., Cotton S.M., Parker A.G., Hetrick S. A systematic review of relapse measurement in randomized controlled trials of relapse prevention in first-episode psychosis. Schizophr. Res. 2010, 119(1-3):79-88.
65. Harvey P.D., Loewenstein D.A., Czaja S.J. Hospitalization and psychosis: influences on the course of cognition and everyday functioning in people with schizophrenia. Neurobiol. Dis. 2013, 53:18-25.
66. Haywood T.W., Kravitz H.M., Grossman L.S., Cavanaugh J.L., Davis J.M., Lewis D.A. Predicting the "revolving door" phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am. J. Psychiatry 1995, 152(6):856-861.
67. Hazlett H., Dawson M.E., Schell A.M., Nuechterlein K.H. Electrodermal activity as a prodromal sign in schizophrenia. Biol. Psychiatry 1997, 41(1):111-113.
68. Hirsch S.R., Jolley A.G. The dysphoric syndrome in schizophrenia and its implications for relapse. Br. J. Psychiatry Suppl. 1989, (5):46-50.
69. Ho B.C., Andreasen N.C., Ziebell S., Pierson R., Magnotta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch. Gen. Psychiatry 2011, 68(2):128-137.
70. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III - the final common pathway. Schizophr. Bull. 2009, 35(3):549-562.
71. Ismail K., Murray R.M., Wheeler M.J., O'Keane V. The dexamethasone suppression test in schizophrenia. Psychol. Med. 1998, 28(2):311-317.
72. Janowsky D.S., el-Yousel M.K., Davis J.M., Sekerke H.J. Provocation of schizophrenic symptoms by intravenous administration of methylphenidate. Arch. Gen. Psychiatry 1973, 28(2):185-191.
73. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988, 45(9):789-796.
74. 2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol. Psychiatry 2001, 50(11):873-883.
75. 2 receptor explain the action of atypical antipsychotics?: A new hypothesis. Am. J. Psychiatry 2001, 158(3):360-369.
76. Kelley M.E., Yao J.K., van Kammen D.P. Plasma catecholamine metabolites as markers for psychosis and antipsychotic response in schizophrenia. Neuropsychopharmacology 1999, 20(6):603-611.
77. Kiefer M., Martens U., Weisbrod M., Hermle L., Spitzer M. Increased unconscious semantic activation in schizophrenia patients with formal thought disorder. Schizophr. Res. 2009, 114(1-3):79-83.
78. Kishimoto T., Agarwal V., Kishi T., Leucht S., Kane J.M., Correll C.U. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol. Psychiatry 2013, 18(1):53-66.
79. Kornetsky C. Hyporesponsivity of chronic schizophrenic patients to dextroamphetamine. Arch. Gen. Psychiatry 1976, 33(12):1425-1428.
80. Kostrzewa R.M., Kostrzewa J.P., Brown R.W., Nowak P., Brus R. Dopamine receptor supersensitivity: development, mechanisms, presentation, and clinical applicability. Neurotox. Res. 2008, 14(2-3):121-128.
81. Koychev I., El-Deredy W., Mukherjee T., Haenschel C., Deakin J.F. Core dysfunction in schizophrenia: electrophysiology trait biomarkers. Acta Psychiatr. Scand. 2012, 126(1):59-71.
82. Kuepper R., Skinbjerg M., Abi-Dargham A. The dopamine dysfunction in schizophrenia revisited: new insights into topography and course. Handb. Exp. Pharmacol. 2012, (212):1-26.
83. Kurachi M., Shibata R., Murata M., Tanii Y. Parallel development of dopamine metabolism tolerance in the rat prefrontal cortex, caudate-putamen, and amygdala following haloperidol decanoate administration. Biol. Psychiatry 1995, 37(7):487-490.
84. Ladea M., Prelipceanu D. Markers of vulnerability in schizophrenia. J. Med. Life 2009, 2(2):155-164.
85. Lader M. What is relapse in schizophrenia?. Int. Clin. Psychopharmacol. 1995, 9(Suppl. 5):5-9.
86. Langer G., Koinig G., Hatzinger R., Schonbeck G., Resch F., Aschauer H., Keshavan M.S., Sieghart W. Response of thyrotropin to thyrotropin-releasing hormone as predictor of treatment outcome. Prediction of recovery and relapse in treatment with antidepressants and neuroleptics. Arch. Gen. Psychiatry 1986, 43(9):861-868.
87. Laruelle M. The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res. Brain Res. Rev. 2000, 31(2-3):371-384.
88. Leucht S., Tardy M., Komossa K., Heres S., Kissling W., Davis J.M. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst. Rev. 2012, 5:CD008016.
89. Levine S.Z., Rabinowitz J. Trajectories and antecedents of treatment response over time in early-episode psychosis. Schizophr. Bull. 2010, 36(3):624-632.
90. Levine S.Z., Rabinowitz J., Case M., Ascher-Svanum H. Treatment response trajectories and their antecedents in recent-onset psychosis: a 2-year prospective study. J. Clin. Psychopharmacol. 2010, 30(4):446-449.
91. Levine S.Z., Lurie I., Kohn R., Levav I. Trajectories of the course of schizophrenia: from progressive deterioration to amelioration over three decades. Schizophr. Res. 2011, 126(1-3):184-191.
92. Levy E., Pawliuk N., Joober R., Abadi S., Malla A. Medication-adherent first-episode psychosis patients also relapse: why?. Can. J. Psychiatry 2012, 57(2):78-84.
93. Lieberman J.A., Kane J.M., Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl.) 1987, 91(4):415-433.
94. Lieberman J.A., Kane J.M., Sarantakos S., Gadaleta D., Woerner M., Alvir J., Ramos-Lorenzi J. Prediction of relapse in schizophrenia. Arch. Gen. Psychiatry 1987, 44(7):597-603.
95. Lieberman J.A., Kinon B.J., Loebel A.D. Dopaminergic mechanisms in idiopathic and drug-induced psychoses. Schizophr. Bull. 1990, 16(1):97-110.
96. Lieberman J., Jody D., Geisler S., Alvir J., Loebel A., Szymanski S., Woerner M., Borenstein M. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch. Gen. Psychiatry 1993, 50(5):369-376.
97. Lieberman J.A., Safferman A.Z., Pollack S., Szymanski S., Johns C., Howard A., Kronig M., Bookstein P., Kane J.M. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am. J. Psychiatry 1994, 151(12):1744-1752.
98. Lieberman J.A., Alvir J.M., Koreen A., Geisler S., Chakos M., Sheitman B., Woerner M. Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology 1996, 14(3 Suppl.):13S-21S.
99. Lindstrom L.H. Clinical and biological markers for outcome in schizophrenia: a review of a longitudinal follow-up study in Uppsala schizophrenia research project. Neuropsychopharmacology 1996, 14(3 Suppl.):23S-26S.
100. Margolese H.C., Chouinard G., Beauclair L., Belanger M.C. Therapeutic tolerance and rebound psychosis during quetiapine maintenance monotherapy in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychopharmacol. 2002, 22(4):347-352.
101. Marques T.R., Arenovich T., Agid O., Sajeev G., Muthen B., Chen L., Kinon B.J., Kapur S. The different trajectories of antipsychotic response: antipsychotics versus placebo. Psychol. Med. 2011, 41(7):1481-1488.
102. Matsuoka H., Matsumoto K., Yamazaki H., Yoshida S., Numachi Y., Saito H., Ueno T., Sato M. Delayed visual NA potential in remitted schizophrenia: a new vulnerability marker for psychotic relapse under low-dose medication. Biol. Psychiatry 1999, 45(1):107-115.
103. McGlashan T.H. Is active psychosis neurotoxic?. Schizophr. Bull. 2006, 32(4):609-613.
104. McKetin R., Lubman D.I., Baker A.L., Dawe S., Ali R.L. Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study. JAMA Psychiatry 2013, 70(3):319-324.
105. Meltzer H.Y., Bastani B., Kwon K.Y., Ramirez L.F., Burnett S., Sharpe J. A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report. Psychopharmacology (Berl.) 1989, (99 Suppl.):S68-S72.
106. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2011, 70(7):663-671.
107. Miller B.J., Gassama B., Sebastian D., Buckley P., Mellor A. Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2013, 73(10):993-999.
108. Mizrahi R., Addington J., Rusjan P.M., Suridjan I., Ng A., Boileau I., Pruessner J.C., Remington G., Houle S., Wilson A.A. Increased stress-induced dopamine release in psychosis. Biol. Psychiatry 2012, 71(6):561-567.
109. Moghaddam B. Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders. Biol. Psychiatry 2002, 51(10):775-787.
110. Molina V., Blanco J.A. A proposal for reframing schizophrenia research. J. Nerv. Ment. Dis. 2013, 201(9):744-752.
111. Moncrieff J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr. Scand. 2006, 114(1):3-13.
112. Moncrieff J., Leo J. A systematic review of the effects of antipsychotic drugs on brain volume. Psychol. Med. 2010, 40(9):1409-1422.
113. Mouaffak F., Tranulis C., Gourevitch R., Poirier M.F., Douki S., Olie J.P., Loo H., Gourion D. Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia. Clin. Neuropharmacol. 2006, 29(1):28-33.
114. Muller N. Mechanisms of relapse prevention in schizophrenia. Pharmacopsychiatry 2004, 37(Suppl. 2):S141-S147.
115. Muller P., Seeman P. Dopaminergic supersensitivity after neuroleptics: time-course and specificity. Psychopharmacology (Berl.) 1978, 60(1):1-11.
116. Myin-Germeys I., Delespaul P., van Os J. Behavioural sensitization to daily life stress in psychosis. Psychol. Med. 2005, 35(5):733-741.
117. Najjar S., Pearlman D.M., Alper K., Najjar A., Devinsky O. Neuroinflammation and psychiatric illness. J. Neuroinflammation 2013, 10:43.
118. National Institute for Health and Clinical Excellence (NICE) NICE clinical guideline 82 - schizophrenia 2009.
119. Navari S., Dazzan P. Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychol. Med. 2009, 39(11):1763-1777.
120. Niemi-Pynttari J.A., Sund R., Putkonen H., Vorma H., Wahlbeck K., Pirkola S.P. Substance-induced psychoses converting into schizophrenia: a register-based study of 18,478 Finnish inpatient cases. J. Clin. Psychiatry 2013, 74(1):e94-e99.
121. Nuechterlein K.H., Dawson M.E., Gitlin M., Ventura J., Goldstein M.J., Snyder K.S., Yee C.M., Mintz J. Developmental processes in schizophrenic disorders: longitudinal studies of vulnerability and stress. Schizophr. Bull. 1992, 18(3):387-425.
122. Ogura C., Kishimoto A., Nakao T. Clinical effect of L-dopa on schizophrenia. Curr. Ther. Res. Clin. Exp. 1976, 20(3):308-318.
123. Olabi B., Ellison-Wright I., McIntosh A.M., Wood S.J., Bullmore E., Lawrie S.M. Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studies. Biol. Psychiatry 2011, 70(1):88-96.
124. Paparelli A., Di Forti M., Morrison P.D., Murray R.M. Drug-induced psychosis: how to avoid star gazing in schizophrenia research by looking at more obvious sources of light. Front. Behav. Neurosci. 2011, 5:1.
125. Parikh V., Evans D.R., Khan M.M., Mahadik S.P. Nerve growth factor in never-medicated first-episode psychotic and medicated chronic schizophrenic patients: possible implications for treatment outcome. Schizophr. Res. 2003, 60(2-3):117-123.
126. Peabody C.A., Whiteford H.A., Warner M.D., Faull K.F., Barchas J.D., Berger P.A. TRH stimulation test and depression. Psychiatry Res. 1987, 22(1):21-28.
127. Pelayo-Teran J.M., Diaz F.J., Perez-Iglesias R., Suarez-Pinilla P., Tabares-Seisdedos R., de Leon J., Crespo-Facorro B. Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis. Psychol. Med. 2013, 1-14.
128. Persson T., Roos B.E. Acid metabolites from monoamines in cerebrospinal fluid of chronic schizophrenics. Br. J. Psychiatry 1969, 115(518):95-98.
129. Post R.M. Cocaine psychoses: a continuum model. Am. J. Psychiatry 1975, 132(3):225-231.
130. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry 2008, 63(8):801-808.
131. Pruessner M., Bechard-Evans L., Boekestyn L., Iyer S.N., Pruessner J.C., Malla A.K. Attenuated cortisol response to acute psychosocial stress in individuals at ultra-high risk for psychosis. Schizophr. Res. 2013, 146(1-3):79-86.
132. Puri B.K. Brain tissue changes and antipsychotic medication. Expert. Rev. Neurother. 2011, 11(7):943-946.
133. Remington G., Kapur S. Antipsychotic dosing: how much but also how often?. Schizophr. Bull. 2010, 36(5):900-903.
134. Remington G., Seeman P., Shammi C., Mann S., Kapur S. "Extended" antipsychotic dosing: rationale and pilot data. J. Clin. Psychopharmacol. 2005, 25(6):611-613.
135. Remington G., Seeman P., Feingold A., Mann S., Shammi C., Kapur S. "Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial. J. Clin. Psychiatry 2011, 72(8):1042-1048.
136. Remington G., Teo C., Mann S., Hahn M., Foussias G., Agid O. Examining levels of antipsychotic adherence to better understand nonadherence. J. Clin. Psychopharmacol. 2013, 33(2):261-263.
137. Robinson D., Woerner M.G., Alvir J.M., Bilder R., Goldman R., Geisler S., Koreen A., Sheitman B., Chakos M., Mayerhoff D., Lieberman J.A. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch. Gen. Psychiatry 1999, 56(3):241-247.
138. Robinson D.G., Woerner M.G., Alvir J.M., Geisler S., Koreen A., Sheitman B., Chakos M., Mayerhoff D., Bilder R., Goldman R., Lieberman J.A. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am. J. Psychiatry 1999, 156(4):544-549.
139. Rutten B.P., Hammels C., Geschwind N., Menne-Lothmann C., Pishva E., Schruers K., van den Hove D., Kenis G., van Os J., Wichers M. Resilience in mental health: linking psychological and neurobiological perspectives. Acta Psychiatr. Scand. 2013, 128(1):3-20.
140. Samaha A.N., Reckless G.E., Seeman P., Diwan M., Nobrega J.N., Kapur S. Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery. Biol. Psychiatry 2008, 64(2):145-152.
141. Schwarz E., Guest P.C., Steiner J., Bogerts B., Bahn S. Identification of blood-based molecular signatures for prediction of response and relapse in schizophrenia patients. Transl. Psychiatry 2012, 2:e82.
142. 2(high) receptors. CNS Neurosci. Ther. 2011, 17(2):118-132.
143. 2 receptors, yet occupy high levels of these receptors. Mol. Psychiatry 1998, 3(2):123-134.
144. 3H](+)PHNO. Synapse 2007, 61(5):263-267.
145. Sernyak M.J., Rosenheck R. Clinicians' reasons for from recommended dosing practices for antipsychotic medications. Adm. Policy Ment. Health 2007, 34(6):540-547.
146. Shi W.X. Electrophysiological characteristics of dopamine neurons: a 35-year update. J. Neural Transm. Suppl. 2009, (73):103-119.
147. Shuto T., Nishi A. Treatment of the psychostimulant-sensitized animal model of schizophrenia. CNS Neurosci. Ther. 2011, 17(2):133-139.
148. Singh M.M., Kay S.R. Dysphoric response to neuroleptic treatment in schizophrenia: its relationship to autonomic arousal and prognosis. Biol. Psychiatry 1979, 14(2):277-294.
149. Snyder S.H. Amphetamine psychosis: a "model" schizophrenia mediated by catecholamines. Am. J. Psychiatry 1973, 130(1):61-67.
150. Sofroniew M.V., Howe C.L., Mobley W.C. Nerve growth factor signaling, neuroprotection, and neural repair. Annu. Rev. Neurosci. 2001, 24:1217-1281.
151. Steinhauer S.R., van Kammen D.P., Colbert K., Peters J.L., Zubin J. Pupillary constriction during haloperidol treatment as a predictor of relapse following drug withdrawal in schizophrenic patients. Psychiatry Res. 1992, 43(3):287-298.
152. Tandon R., Nasrallah H.A., Keshavan M.S. Schizophrenia, "just the facts" 4. Clinical features and conceptualization. Schizophr. Res. 2009, 110(1-3):1-23.
153. Tenn C.C., Fletcher P.J., Kapur S. A putative animal model of the "prodromal" state of schizophrenia. Biol. Psychiatry 2005, 57(6):586-593.
154. Tessner K.D., Mittal V., Walker E.F. Longitudinal study of stressful life events and daily stressors among adolescents at high risk for psychotic disorders. Schizophr. Bull. 2011, 37(2):432-441.
155. van der Werff S.J., van den Berg S.M., Pannekoek J.N., Elzinga B.M., van der Wee N.J. Neuroimaging resilience to stress: a review. Front. Behav. Neurosci. 2013, 7:39.
156. van Harten P.N., Tenback D.E. Tardive dyskinesia: clinical presentation and treatment. Int. Rev. Neurobiol. 2011, 98:187-210.
157. van Kammen D.P., Schooler N. Are biochemical markers for treatment-resistant schizophrenia state dependent or traits?. Clin. Neuropharmacol. 1990, 13(Suppl. 1):S16-S28.
158. van Kammen D.P., Bunney W.E., Docherty J.P., Marder S.R., Ebert M.H., Rosenblatt J.E., Rayner J.N. d-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia. Am. J. Psychiatry 1982, 139(8):991-997.
159. van Kammen D.P., Peters J., van Kammen W.B., Nugent A., Goetz K.L., Yao J., Linnoila M. CSF norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal. Biol. Psychiatry 1989, 26(2):176-188.
160. van Kammen D.P., Agren H., Yao J.K., O'Connor D.T., Gurklis J., Peters J.L. Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia. Am. J. Psychiatry 1994, 151(3):379-384.
161. van Kammen D.P., Kelley M.E., Gurklis J.A., Gilbertson M.W., Yao J.K., Peters J.L. Behavioral vs biochemical prediction of clinical stability following haloperidol withdrawal in schizophrenia. Arch. Gen. Psychiatry 1995, 52(8):673-678.
162. Velakoulis D., Wood S.J., Wong M.T., McGorry P.D., Yung A., Phillips L., Smith D., Brewer W., Proffitt T., Desmond P., Pantelis C. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Arch. Gen. Psychiatry 2006, 63(2):139-149.
163. Ventura J., Hellemann G.S., Thames A.D., Koellner V., Nuechterlein K.H. Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis. Schizophr. Res. 2009, 113(2-3):189-199.
164. Vernon A.C., Natesan S., Modo M., Kapur S. Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation. Biol. Psychiatry 2011, 69(10):936-944.
165. Vidal C.N., Rapoport J.L., Hayashi K.M., Geaga J.A., Sui Y., McLemore L.E., Alaghband Y., Giedd J.N., Gochman P., Blumenthal J., Gogtay N., Nicolson R., Toga A.W., Thompson P.M. Dynamically spreading frontal and cingulate deficits mapped in adolescents with schizophrenia. Arch. Gen. Psychiatry 2006, 63(1):25-34.
166. Viguera A.C., Baldessarini R.J., Hegarty J.D., van Kammen D.P., Tohen M. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch. Gen. Psychiatry 1997, 54(1):49-55.
167. Walker E.F., Diforio D. Schizophrenia: a neural diathesis-stress model. Psychol. Rev. 1997, 104(4):667-685.
168. Weinberger D. Schizophrenia, the prefrontal cortex, and a mechanism of genetic susceptibility. Eur. Psychiatry 2002, 17:355-362.
169. Wiegering V., Eyrich M., Wunder C., Gunther H., Schlegel P.G., Winkler B. Age-related changes in intracellular cytokine expression in healthy children. Eur. Cytokine Netw. 2009, 20(2):75-80.
170. Wisdom J.P., Manuel J.I., Drake R.E. Substance use disorder among people with first-episode psychosis: a systematic review of course and treatment. Psychiatr. Serv. 2011, 62(9):1007-1012.
171. Yui K., Goto K., Ikemoto S., Ishiguro T., Angrist B., Duncan G.E., Sheitman B.B., Lieberman J.A., Bracha S.H., Ali S.F. Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitization. Mol. Psychiatry 1999, 4(6):512-523.
172. Yuii K., Suzuki M., Kurachi M. Stress sensitization in schizophrenia. Ann. N. Y. Acad. Sci. 2007, 1113:276-290.
173. Zahn T.P., Rumsey J.M., Van Kammen D.P. Autonomic nervous system activity in autistic, schizophrenic, and normal men: effects of stimulus significance. J. Abnorm. Psychol. 1987, 96(2):135-144.
174. Zipursky R.B., Reilly T.J., Murray R.M. The myth of schizophrenia as a progressive brain disease. Schizophr. Bull. 2012, (in press, Dec 7, Epub ahead of print).
175. Zubin J., Steinhauer S., Condray R. Vulnerability to relapse in schizophrenia. Br. J. Psychiatry 1992, 161:13-18. (Suppl.).
176. 2 receptor plasticity contributes to stress resilience in rats subjected to chronic mild stress. Psychopharmacology (Berl.) 2013, 227(4):583-593.